Lexicon Pharmaceuticals LXRX Gross realized gains (losses)

Gross realized gains (losses) at other companies

Ionis PharmaceuticalsIONS

——

Revenue$21.1M+1,572%

Gross profit$21.0M+1,604%

Operating income-$996.0K+96.1%

Net income-$1.0M+95.9%

EPS (diluted)$0.00+100%

Cash & equivalents$67.1M+6.7%

Total debt$57.7M-45.7%

Total equity$202.9M+64.9%

Total assets$268.8M-9.7%

Operating cash flow-$14.7M+66.4%

CapEx--100%

Free cash flow-$17.2M+21.5%

Market cap$986.12M+273%

Enterprise value$976.73M+219%

P/S14.2×+5.7×

Gross margin99.5%+1.5pp

Operating margin-34.8%-16.8pp

Net margin-37.5%-18.1pp

FCF margin-578.5%-283pp

Return on equity-16%-7.2pp

Debt / equity0.3×-0.6×

Current ratio18.8×+16.6×

Reported directly by Lexicon Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RealizedInvestmentGainsLosses.

The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Lexicon Pharmaceuticals's gross realized gains (losses)?: Lexicon Pharmaceuticals (LXRX) reported gross realized gains (losses) of $100K in Q1 2026.